Rofecoxib administration to paediatric patients undergoing adenotonsillectomy
- 1 July 2004
- journal article
- research article
- Published by Wiley in Pediatric Anesthesia
- Vol. 14 (7), 579-583
- https://doi.org/10.1111/j.1460-9592.2004.01263.x
Abstract
Rofecoxib is a selective COX-2 inhibitor that does not interfere with platelet function and is associated with fewer bleeding complications than other nonsteroidal anti-inflammatory agents (NSAIDs). Our aims were to evaluate the safety and the efficacy of rofecoxib administration to paediatric patients undergoing adenotonsillectomy (T&A). We conducted a double-blind, randomized, placebo-controlled study of rofecoxib in 45 ASA 1-2 patients > or = 4 years of age undergoing outpatient T&A. All patients received midazolam 0.5 mg x kg(-1) (max 15 mg) p.o. and either rofecoxib 1 mg x .kg(-1) (max 25 mg) or placebo p.o. 30 min preoperatively. All patients had a standardized anaesthetic and were extubated awake in the operating room at the conclusion of surgery. The Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) scores were obtained on arrival in the postanaesthetic care unit (PACU). Morphine 25 microg x kg(-1) i.v. were administered up to six times for pain in the PACU. Wong-Baker FACES Scales were obtained at discharge from the PACU and the day surgery unit (DSU). Outcome measures included intraoperative estimated blood loss (EBL), pain scores, PACU morphine requirements and discharge times. There were 23 patients in the rofecoxib group and 22 patients in the placebo group. There were no differences between the rofecoxib and placebo groups in terms of bleeding, pain scores, PACU morphine requirements, PACU times or DSU times. Rofecoxib administration to paediatric patients undergoing T&A did not result in increased bleeding. Rofecoxib, however, was not found to decrease morphine use or improve pain scores prior to hospital discharge in T&A patients who received intraoperative morphine and acetaminophen.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trialArthritis & Rheumatism, 2000
- Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.Jama-Journal Of The American Medical Association, 1999
- RofecoxibDrugs, 1999
- Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomyActa Anaesthesiologica Scandinavica, 1998
- Complications of Tonsillectomy and AdenoidectomyOtolaryngology -- Head and Neck Surgery, 1998
- Intraoperative Ketorolac and Posttonsillectomy BleedingJAMA Otolaryngology–Head & Neck Surgery, 1996
- Preoperative ketorolac increases bleeding after tonsillectomy in childrenCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1996
- Pain after tonsillectomyClinical Otolaryngology, 1996
- Perioperative ketorolac tromethamine and postoperative hemorrhage in cases of tonsillectomy and adenoidectomyThe Laryngoscope, 1995
- Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomyPain, 1995